ADMA Biologics Raises 2026 Guidance, Projects Strong Long-Term Growth to $1.1B Revenue by 2029
ADMA sits 34% above its 52-week low of $13.5.
Summary
ADMA Biologics announced preliminary unaudited full year 2025 revenue meeting guidance, and significantly raised its financial outlook for 2026 and beyond, projecting over $1.1 billion in annual revenue by 2029.
Key Events · Earnings and Guidance · ADMA
-
Raised 2026 Financial Guidance
The company increased its expected total revenue for fiscal year 2026 to approximately $635 million (up from $630 million) and Adjusted EBITDA to approximately $360 million (up from $355 million).
-
Strong Long-Term Growth Targets
ADMA introduced new fiscal year 2027 guidance, projecting approximately $775 million in total revenue and $455 million in Adjusted EBITDA. It also targets over $1.1 billion in annual revenue and $700 million in Adjusted EBITDA by fiscal year 2029.
-
Strategic Operational Enhancements
ADMA successfully implemented yield-enhanced production, with 2026 expected to be the first full year of monetizing this. The company also repositioned its plasma collection network, divesting three centers for $12 million and securing long-term plasma supply agreements to enhance margins and supply visibility.
-
Solid 2025 Performance
Preliminary unaudited full year 2025 total revenue is estimated at $510-$511 million, meeting or exceeding prior guidance. The company ended 2025 with approximately $88 million in cash, including $40 million in operating cash flow generated in Q4 2025.
Analysis · ADMA · Life Sciences
ADMA Biologics delivered a comprehensive positive update, significantly raising its financial outlook for 2026 and providing robust long-term targets through 2029. The increased revenue and Adjusted EBITDA guidance for 2026, coupled with new, strong projections for 2027 and a target of over $1.1 billion in annual revenue by 2029, signals accelerating growth and expanding profitability. Strategic operational improvements, such as the successful implementation of yield-enhanced production and the repositioning of its plasma network, are expected to drive margin expansion and ensure long-term supply. These factors collectively indicate strong business momentum and management's confidence in future performance.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADMA was trading at $18.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $13.50 to $25.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.